Shattuck Labs Prices $75M Public Offering at $4/Share, Significant Dilution Expected
STTK has more than doubled off its 52-week low of $0.712 on elevated volume (2.3× avg).
Summary
Shattuck Labs has priced its public offering, raising $75 million by selling 10.88 million shares at $4.00 each. This follows yesterday's announcement of the offering's commencement and recent news of positive Phase 1 clinical trial results and a $54.9 million cash infusion from warrant exercises. The offering is highly dilutive, representing approximately 23% of the company's current market capitalization, and is priced below the current market price. While it bolsters the company's cash position, the terms are unfavorable for existing shareholders.
At the time of this announcement, STTK was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $327.4M. The 52-week trading range was $0.71 to $8.33. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.